Cargando…

Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada

OBJECTIVE: Real‐world clinical effectiveness of liraglutide 3.0 mg, in combination with diet and exercise, was investigated 4 and 6 months post initiation. Changes in absolute and percent body weight were examined from baseline. METHODS: A cohort of liraglutide 3.0 mg initiators in 2015 and 2016 was...

Descripción completa

Detalles Bibliográficos
Autores principales: Wharton, Sean, Liu, Aiden, Pakseresht, Arash, Nørtoft, Emil, Haase, Christiane L., Mancini, Johanna, Power, G. Sarah, Vanderlelie, Sarah, Christensen, Rebecca A. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593982/
https://www.ncbi.nlm.nih.gov/pubmed/31062937
http://dx.doi.org/10.1002/oby.22462
_version_ 1783430165153447936
author Wharton, Sean
Liu, Aiden
Pakseresht, Arash
Nørtoft, Emil
Haase, Christiane L.
Mancini, Johanna
Power, G. Sarah
Vanderlelie, Sarah
Christensen, Rebecca A. G.
author_facet Wharton, Sean
Liu, Aiden
Pakseresht, Arash
Nørtoft, Emil
Haase, Christiane L.
Mancini, Johanna
Power, G. Sarah
Vanderlelie, Sarah
Christensen, Rebecca A. G.
author_sort Wharton, Sean
collection PubMed
description OBJECTIVE: Real‐world clinical effectiveness of liraglutide 3.0 mg, in combination with diet and exercise, was investigated 4 and 6 months post initiation. Changes in absolute and percent body weight were examined from baseline. METHODS: A cohort of liraglutide 3.0 mg initiators in 2015 and 2016 was identified from six Canadian weight‐management clinics. Post initiation values at 4 and 6 months were compared with baseline values using a paired t test. RESULTS: The full cohort consisted of 311 participants, with 210 in the ≥ 4‐month persistence group and 167 in the ≥ 6‐month persistence group. Average baseline BMI was 40.7 kg/m(2), and weight was 114.8 kg. There was a significant change in body weight 6 and 4 months after initiation of treatment in persistent subjects (≥ 6‐month: −8.0 kg, P < 0.001; ≥ 4‐month: −7.0 kg, P < 0.001) and All Subjects, regardless of persistence (−7.3 kg; P < 0.001). Percentage change in body weight from baseline was −7.1% in the ≥ 6‐month group and −6.3% in the ≥ 4‐month group, and All Subjects lost 6.5% body weight. Of participants in the ≥ 6‐month group, 64.10% and 34.5% lost ≥ 5% and > 10% body weight, respectively. CONCLUSIONS: In a real‐world setting, liraglutide 3.0 mg, when combined with diet and exercise, was associated with clinically meaningful weight loss.
format Online
Article
Text
id pubmed-6593982
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65939822019-07-10 Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada Wharton, Sean Liu, Aiden Pakseresht, Arash Nørtoft, Emil Haase, Christiane L. Mancini, Johanna Power, G. Sarah Vanderlelie, Sarah Christensen, Rebecca A. G. Obesity (Silver Spring) Original Articles OBJECTIVE: Real‐world clinical effectiveness of liraglutide 3.0 mg, in combination with diet and exercise, was investigated 4 and 6 months post initiation. Changes in absolute and percent body weight were examined from baseline. METHODS: A cohort of liraglutide 3.0 mg initiators in 2015 and 2016 was identified from six Canadian weight‐management clinics. Post initiation values at 4 and 6 months were compared with baseline values using a paired t test. RESULTS: The full cohort consisted of 311 participants, with 210 in the ≥ 4‐month persistence group and 167 in the ≥ 6‐month persistence group. Average baseline BMI was 40.7 kg/m(2), and weight was 114.8 kg. There was a significant change in body weight 6 and 4 months after initiation of treatment in persistent subjects (≥ 6‐month: −8.0 kg, P < 0.001; ≥ 4‐month: −7.0 kg, P < 0.001) and All Subjects, regardless of persistence (−7.3 kg; P < 0.001). Percentage change in body weight from baseline was −7.1% in the ≥ 6‐month group and −6.3% in the ≥ 4‐month group, and All Subjects lost 6.5% body weight. Of participants in the ≥ 6‐month group, 64.10% and 34.5% lost ≥ 5% and > 10% body weight, respectively. CONCLUSIONS: In a real‐world setting, liraglutide 3.0 mg, when combined with diet and exercise, was associated with clinically meaningful weight loss. John Wiley and Sons Inc. 2019-05-07 2019-06 /pmc/articles/PMC6593982/ /pubmed/31062937 http://dx.doi.org/10.1002/oby.22462 Text en © 2019 The Authors. Obesity published by Wiley Periodicals, Inc. on behalf of The Obesity Society (TOS) This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Wharton, Sean
Liu, Aiden
Pakseresht, Arash
Nørtoft, Emil
Haase, Christiane L.
Mancini, Johanna
Power, G. Sarah
Vanderlelie, Sarah
Christensen, Rebecca A. G.
Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
title Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
title_full Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
title_fullStr Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
title_full_unstemmed Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
title_short Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
title_sort real‐world clinical effectiveness of liraglutide 3.0 mg for weight management in canada
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593982/
https://www.ncbi.nlm.nih.gov/pubmed/31062937
http://dx.doi.org/10.1002/oby.22462
work_keys_str_mv AT whartonsean realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada
AT liuaiden realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada
AT paksereshtarash realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada
AT nørtoftemil realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada
AT haasechristianel realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada
AT mancinijohanna realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada
AT powergsarah realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada
AT vanderleliesarah realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada
AT christensenrebeccaag realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada